Literature DB >> 2553730

Herpes simplex virus type 1 and human DNA polymerase interactions with 2'-deoxyguanosine 5'-triphosphate analogues. Kinetics of incorporation into DNA and induction of inhibition.

J E Reardon1.   

Abstract

The ability of herpes simplex virus type 1 (HSV-1) DNA polymerase, HeLa polymerase alpha, and HeLa polymerase beta to utilize several dGTP analogues has been investigated using a defined synthetic template primer. The relative efficiencies of the triphosphates of 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir triphosphate, ACVTP), 9-[(1,3-dihydroxy-2-propoxy)methyl] guanine (ganciclovir triphosphate, DHPGTP), and 2',3'-dideoxyguanosine (ddGTP) as substrates for the three polymerases were: HSV-1 polymerase, dGTP greater than ACVTP approximately equal to DHPGTP greater than ddGTP; polymerase alpha, dGTP greater than ACVTP approximately equal to DHPGTP much greater than ddGTP; polymerase beta, ddGTP greater than dGTP much greater than ACVTP approximately equal to DHPGTP. The potent inhibition of HSV-1 polymerase by ACVTP has been shown previously to be due to the formation of a dead-end complex upon binding of the next 2'-deoxynucleoside 5'-triphosphate encoded by the template after incorporation of acyclovir monophosphate into the 3' end of the primer (Reardon, J. E., and Spector, T. (1989) J. Biol. Chem. 264, 7405-7411). This mechanism was shown here to be a general mechanism for inhibition of polymerases by the obligate chain terminators, ACVTP and ddGTP. The ACVTP-induced inhibition was 30-fold more potent with HSV-1 polymerase than with polymerase alpha. This difference may contribute to the antiviral selectivity of this nucleotide analogue. The effect of ganciclovir monophosphate incorporation (a nonobligate chain terminator) on subsequent primer extension was also evaluated. With HSV-1 polymerase and polymerase alpha, although there was a considerable reduction in the efficiency of utilization of the 3'-DHPGMP-terminal primer, contrasting kinetic behavior was observed. With HSV-1 polymerase, insertion of DHPGTP resulted in a significant reduction in Vmax for subsequent nucleotide incorporations. In contrast, with polymerase alpha, a relatively small decrease in Vmax was accompanied by increased Km values for subsequent nucleotide incorporations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553730

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.

Authors:  Egor P Tchesnokov; Aleksandr Obikhod; Raymond F Schinazi; Matthias Götte
Journal:  J Biol Chem       Date:  2009-07-21       Impact factor: 5.157

2.  Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis.

Authors:  J L Martin; C E Brown; N Matthews-Davis; J E Reardon
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

3.  Identification of the lytic origin of DNA replication in human cytomegalovirus by a novel approach utilizing ganciclovir-induced chain termination.

Authors:  F M Hamzeh; P S Lietman; W Gibson; G S Hayward
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

4.  Herpes simplex virus DNA packaging without measurable DNA synthesis.

Authors:  G A Church; A Dasgupta; D W Wilson
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

Review 5.  Mechanistic cross-talk between DNA/RNA polymerase enzyme kinetics and nucleotide substrate availability in cells: Implications for polymerase inhibitor discovery.

Authors:  Si'Ana A Coggins; Bijan Mahboubi; Raymond F Schinazi; Baek Kim
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

6.  Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity.

Authors:  Jessica J O'Konek; Brendon Ladd; Sheryl A Flanagan; Mike M Im; Paul D Boucher; Tico S Thepsourinthone; John A Secrist; Donna S Shewach
Journal:  Mutat Res       Date:  2010-01-08       Impact factor: 2.433

Review 7.  Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas.

Authors:  Prakash Rath; Huidong Shi; Joel A Maruniak; N Scott Litofsky; Bernard L Maria; Mark D Kirk
Journal:  Curr Stem Cell Res Ther       Date:  2009-01       Impact factor: 3.828

8.  The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.

Authors:  Moira A McMahon; Janet D Siliciano; Jun Lai; Jun O Liu; James T Stivers; Robert F Siliciano; Rahul M Kohli
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

9.  Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus.

Authors:  D L Earnshaw; T H Bacon; S J Darlison; K Edmonds; R M Perkins; R A Vere Hodge
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

10.  Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo.

Authors:  A Ardiani; M Sanchez-Bonilla; M E Black
Journal:  Cancer Gene Ther       Date:  2009-09-18       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.